WO2011050211A3 - Procédés et compositions pour troubles associés à la prolifération cellulaire - Google Patents

Procédés et compositions pour troubles associés à la prolifération cellulaire Download PDF

Info

Publication number
WO2011050211A3
WO2011050211A3 PCT/US2010/053624 US2010053624W WO2011050211A3 WO 2011050211 A3 WO2011050211 A3 WO 2011050211A3 US 2010053624 W US2010053624 W US 2010053624W WO 2011050211 A3 WO2011050211 A3 WO 2011050211A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
proliferation
cell
related disorders
Prior art date
Application number
PCT/US2010/053624
Other languages
English (en)
Other versions
WO2011050211A2 (fr
Inventor
Shinsan Su
Lenny Dang
Stefan Gross
Shengfang Jin
Lewis C. Cantley
Jeffrey O. Saunders
Valeria Fantin
Original Assignee
Agios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.
Priority to EP10825707.2A priority Critical patent/EP2525790B1/fr
Priority to ES10825707T priority patent/ES2812537T3/es
Priority to CA2793836A priority patent/CA2793836C/fr
Publication of WO2011050211A2 publication Critical patent/WO2011050211A2/fr
Publication of WO2011050211A3 publication Critical patent/WO2011050211A3/fr
Priority to US13/619,387 priority patent/US8883438B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des compositions pour le traitement et l'évaluation de sujets présentant une mutation néo-active au niveau du résidu 97 d'IDH1 ou 137 d'IDH2.
PCT/US2010/053624 2009-10-21 2010-10-21 Procédés et compositions pour troubles associés à la prolifération cellulaire WO2011050211A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP10825707.2A EP2525790B1 (fr) 2009-10-21 2010-10-21 Procédés et compositions pour troubles associés à la prolifération cellulaire
ES10825707T ES2812537T3 (es) 2009-10-21 2010-10-21 Métodos y composiciones para trastornos relacionados con la proliferación celular
CA2793836A CA2793836C (fr) 2009-10-21 2010-10-21 Procedes et compositions pour troubles associes a la proliferation cellulaire
US13/619,387 US8883438B2 (en) 2009-10-21 2012-09-14 Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25381809P 2009-10-21 2009-10-21
US61/253,818 2009-10-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/619,387 Continuation US8883438B2 (en) 2009-10-21 2012-09-14 Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1

Publications (2)

Publication Number Publication Date
WO2011050211A2 WO2011050211A2 (fr) 2011-04-28
WO2011050211A3 true WO2011050211A3 (fr) 2011-06-16

Family

ID=43900969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/053624 WO2011050211A2 (fr) 2009-10-21 2010-10-21 Procédés et compositions pour troubles associés à la prolifération cellulaire

Country Status (5)

Country Link
US (1) US8883438B2 (fr)
EP (1) EP2525790B1 (fr)
CA (1) CA2793836C (fr)
ES (1) ES2812537T3 (fr)
WO (1) WO2011050211A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844787B2 (en) 2018-09-19 2023-12-19 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US12122778B2 (en) 2019-09-19 2024-10-22 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
EP3064595B1 (fr) * 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Procédés pour des troubles liés à la prolifération cellulaire
KR101159000B1 (ko) * 2010-06-18 2012-06-21 (주) 에빅스젠 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
US11262362B2 (en) 2011-11-18 2022-03-01 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
CN115521264A (zh) 2012-01-06 2022-12-27 法国施维雅药厂 治疗活性化合物及其使用方法
EP2939021A4 (fr) * 2012-12-30 2016-09-07 Brigham & Womens Hospital Système et procédé d'analyse de biométabolites destinés à être utilisés dans une chirurgie guidée par image
EA032070B1 (ru) 2013-07-11 2019-04-30 Аджиос Фармасьютикалз, Инк. Соединения n,6-бис(арил или гетероарил)-1,3,5-триазин-2,4-диамина в качестве ингибиторов мутантов idh2 для лечения ракового заболевания
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015148950A1 (fr) 2014-03-28 2015-10-01 Memorial Sloan-Kettering Cancer Center Métabolisme induit par stress et l-2-hydroxyglutarate
US10703746B2 (en) 2014-12-22 2020-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
SG10201912869WA (en) * 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
US10905692B2 (en) * 2015-10-15 2021-02-02 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
WO2018126467A1 (fr) * 2017-01-09 2018-07-12 深圳市邦泰绿色生物合成研究院 PROCÉDÉ DE PRÉPARATION D'ACIDE 3α-HYDROXY-7-OXO-5β-CHOLANOÏQUE ET ENZYME 2 POUR SA PRÉPARATION
CN110573518A (zh) 2017-01-26 2019-12-13 尤拉·S·赞特里佐斯 被取代的双环嘧啶基化合物及其组合物和用途
NZ763766A (en) 2017-03-20 2023-07-28 Novo Nordisk Healthcare Ag Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
US10996224B2 (en) 2017-03-21 2021-05-04 Mayo Foundation For Medical Education And Research Assessing and treating precursor plasma cell disorders
EP3638245A1 (fr) * 2017-06-12 2020-04-22 Agios Pharmaceuticals, Inc. Méthodes de traitement de tumeurs cérébrales à l'aide d'une polythérapie
US20210196701A1 (en) 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
EP3852791B1 (fr) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activation de la pyruvate kinase r

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
EP0385237B1 (fr) 1989-03-03 1994-06-29 Dainippon Pharmaceutical Co., Ltd. Dérivés de 2-(1-pipérazinyl)-4-phénylcycloalkynopyridines, procédés de préparation et compositions pharmaceutiques les contenant
JPH0491034A (ja) 1990-08-02 1992-03-24 Fujimoto Daiagunosuteitsukusu:Kk 中枢神経保護剤
US5690944A (en) 1994-12-20 1997-11-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing lactate dehydrogenase inhibitors
US6124498A (en) 1995-04-28 2000-09-26 University Of New Mexico Hydroxynaphthoic acids and derivatives
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
JP3234450B2 (ja) 1995-06-29 2001-12-04 株式会社クボタ 収穫機の引起し装置
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
WO1998036774A1 (fr) 1996-12-18 1998-08-27 The Johns Hopkins University School Of Medicine Methode de traitement d'un trouble associe a la lacticodeshydrogenase-a (ldh-a)
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
CA2382789A1 (fr) 1999-08-27 2001-03-08 Sugen, Inc. Mimetiques phosphates et procedes de traitement utilisant des inhibiteurs de phosphatase
AU6715200A (en) 1999-09-04 2001-04-10 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
ES2433476T3 (es) 2000-01-21 2013-12-11 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
MXPA03000458A (es) 2000-07-20 2004-06-02 Neurogen Corp Ligandos receptores de capsaicina.
KR100455899B1 (ko) 2000-10-20 2004-11-08 주식회사 티지 바이오텍 이소시트릭산 탈수소화 효소 및 그의 유전자 그리고 이효소의 활성 및 그 유전자의 발현을 저해하는 비만,고지혈증, 지방간 등을 포함하는 대사성 질환 치료제의 선별 방법
WO2002081751A2 (fr) 2001-04-03 2002-10-17 The Regents Of The University Of California Procede permettant d'augmenter la production de leptine endogene
WO2002095063A1 (fr) 2001-05-23 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pyruvate-kinase utilisee comme nouvelle molecule cible
KR100442322B1 (ko) 2001-06-14 2004-07-30 주식회사 티지 바이오텍 이소시트릭산 탈수소화효소 활성 저해제를 유효성분으로포함하는 비만, 고지혈증 또는 지방간 예방 또는 치료제
AU2003299641C1 (en) 2002-12-16 2016-06-02 Cormorant Pharmaceuticals Ab Human monoclonal antibodies against interleukin 8 (IL-8)
BRPI0406667A (pt) 2003-01-10 2005-12-20 Threshold Pharmaceuticals Inc Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004074438A2 (fr) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Antagonistes de ccr8
WO2004073619A2 (fr) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Antagonistes du recepteur ccr8
KR20050036293A (ko) 2003-10-15 2005-04-20 동아제약주식회사 나프토퀴논계 화합물을 함유한 세포질형 이소시트릭산탈수소화효소 활성 저해제 및 비만과 고지혈증 예방 또는치료용 약학적 조성물
EP1730310A2 (fr) 2004-03-22 2006-12-13 The Regents Of The University Of California Formulation pour ameliorer la production de leptine et d'adiponectine endogene
EP1778616A1 (fr) 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-kétoglutarates et leur utilisation en tant qu'agents thérapeutiques
WO2006042062A2 (fr) 2004-10-08 2006-04-20 The Johns Hopkins University Pyruvate deshydrogenase kinases utiles en tant que cibles therapeutiques pour le cancer et les maladies ischemiques
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
WO2006125323A1 (fr) 2005-05-27 2006-11-30 Darwin Pharma Inc Nouveaux inhibiteurs de la pyruvate kinase comme agents therapeutiques anticancereux
CA2611728A1 (fr) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methode d'identification, d'evaluation et de traitement de patients suivant un traitement anticancereux
ZA200801822B (en) 2005-08-26 2009-09-30 Serono Lab Pyrazine derivatives and use as p13k inhibitors
ES2614931T3 (es) 2006-08-04 2017-06-02 Beth Israel Deaconess Medical Center Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad
WO2008131547A1 (fr) 2007-04-30 2008-11-06 Prometic Biosciences Inc. Dérivés de triazine, compositions contenant de tels dérivés et procédés de traitement du cancer et de maladies auto-immunes par ces dérivés
WO2008156783A2 (fr) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Famille d'inhibiteurs de pfkfb3 à activités anti-néoplasiques
US8299057B2 (en) 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
DK2546365T3 (en) 2008-09-03 2017-01-16 Univ Johns Hopkins Genetic changes of isocitrate dehydrogenase and other genes in malignant glioma
US20120121515A1 (en) * 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
JP2012529511A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
ES2582535T3 (es) 2009-07-10 2016-09-13 Kirk Promotion Ltd. Dispositivo de articulación de la rodilla
EP3064595B1 (fr) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Procédés pour des troubles liés à la prolifération cellulaire
EP2509600B1 (fr) 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh
CA2805669C (fr) 2010-07-16 2018-08-21 Agios Pharmaceuticals, Inc. Compositions therapeutiquement actives et methode d'utilisation correspondante
CN115521264A (zh) 2012-01-06 2022-12-27 法国施维雅药厂 治疗活性化合物及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLEEKER ET AL.: "IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.", HUM MUTATION, vol. 30, no. 1, January 2009 (2009-01-01), pages 7 - 11, XP002555010, DOI: doi:10.1002/humu.20937 *
DANG ET AL.: "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.", NATURE, vol. 462, no. 7274, 22 November 2009 (2009-11-22), pages 739 - 744, XP055009217, DOI: doi:10.1038/nature08617 *
HARTMANN ET AL.: "Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.", ACTA NEUROPATHOL, vol. 118, no. 4, 25 June 2009 (2009-06-25), pages 469 - 474, XP019739824, DOI: doi:10.1007/s00401-009-0561-9 *
YAN ET AL.: "IDH1 and IDH2 Mutations in Gliomas.", NEW ENG J MED, vol. 360, no. 8, 19 February 2009 (2009-02-19), pages 765 - 773, XP002555011, DOI: doi:10.1056/NEJMoa0808710 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844787B2 (en) 2018-09-19 2023-12-19 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US12122778B2 (en) 2019-09-19 2024-10-22 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Also Published As

Publication number Publication date
ES2812537T3 (es) 2021-03-17
WO2011050211A2 (fr) 2011-04-28
US8883438B2 (en) 2014-11-11
EP2525790A4 (fr) 2013-07-31
CA2793836A1 (fr) 2011-04-28
EP2525790A2 (fr) 2012-11-28
US20130316385A1 (en) 2013-11-28
CA2793836C (fr) 2020-03-24
EP2525790B1 (fr) 2020-05-27

Similar Documents

Publication Publication Date Title
WO2011050211A3 (fr) Procédés et compositions pour troubles associés à la prolifération cellulaire
AU2016204346A1 (en) Methods and compositions for cell-proliferation-related disorders
EP2170309A4 (fr) Procédés et compositions pour le traitement de troubles
WO2011016840A3 (fr) Procédés et compositions de traitement de troubles de répétition tri-nucléotidique
PT2374472T (pt) Composições e métodos para o tratamento de afeções oftalmológicas
HK1248543A1 (zh) 改善認知功能的方法和組合物
IL209032A0 (en) Compositions and methods for treating digestive disorders
HK1174064A1 (zh) 用於細胞增殖相關的疾病的方法和組合物
IL208366A0 (en) Compositions and methods for treating and diagnosing asthma
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
EP2320731A4 (fr) Procédés et compositions pour les troubles du sommeil et d autres troubles
WO2011049960A9 (fr) Compositions et méthodes pour le traitement des troubles nasosinusiens
GB2466912B (en) Compositions and methods for treating lysosomal disorders
EP2309858A4 (fr) Compositions et procédés de traitement de troubles inflammatoires
EP2034989A4 (fr) Procédés et compositions permettant d'améliorer la fonction cognitive
EP2074224A4 (fr) Procédé et compositions pour vérification des fonctions et troubles pulmonaires
HK1170150A1 (en) New compositions for treating cmt and related disorders
ZA201203002B (en) Compositions and methods for treating inflammatory disorders
EP2490721A4 (fr) Compositions, procédés de traitement et de diagnostic de troubles liés à l'auto-immunité et procédé de fabrication de telles compositions
EP2271370A4 (fr) Compositions et procédés pour diagnostiquer et traiter un mélanome
EP2077838A4 (fr) Procedes pour le traitement de troubles en rapport avec a , et compositions pour ceux-ci
WO2011079307A3 (fr) Méthodes et compositions pour traiter des troubles neurologiques
EP2120994A4 (fr) Procédés et compositions de traitement de troubles hypoglycémiques
EP2515925A4 (fr) Compositions et méthodes pour prévenir et traiter les maladies et les troubles de santé induits par l'environnement
EP2129795A4 (fr) Procédés et compositions pour l'évaluation de la fonction et de troubles cardiovasculaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10825707

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010825707

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2793836

Country of ref document: CA